Behavioral and molecular actions of caffeine: focus on adenosine.
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000241:Adenosine / Q000378:metabolism* / Q000502:physiology; D000818:Animals; D001008:Anxiety Disorders / Q000175:diagnosis; D001519:Behavior / Q000187:drug effects*; D002110:Caffeine / Q000009:adverse effects / Q000494:pharmacology*; D002648:Child; D000242:Cyclic AMP / Q000378:metabolism; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D010660:Phenylisopropyladenosine / Q000494:pharmacology; D011597:Psychomotor Performance / Q000187:drug effects; D051381:Rats; D011956:Receptors, Cell Surface / Q000187:drug effects; D011983:Receptors, Purinergic; D012640:Seizures / Q000139:chemically induced; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D013268:Stimulation, Chemical; D013662:Tea / Q000009:adverse effects; D014970:Xanthines / Q000009:adverse effects / Q000494:pharmacology
D011956:Receptors, Cell Surface; D011983:Receptors, Purinergic; D013662:Tea; D014970:Xanthines; D010660:Phenylisopropyladenosine; D002110:Caffeine; D000242:Cyclic AMP; D000241:Adenosine; D015056:1-Methyl-3-isobutylxanthine